Physician profile
Allison S Falcone
NPI 1427437995
$4,234.29
in general payments reported to CMS, 2019-2025
26 companies · $664 in 2025
The $664 reported for 2025 was more than what 91% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $1,285 · 2023: $810 · 2024: $550 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.99 | 2021-2023 | |
| Evofem Biosciences, INC. | $710.28 | 2021-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $623.32 | 2021-2023 | Balcoltra, NP Thyroid 60 |
| Exeltis, USA INC. | $579.01 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $332.46 | 2022-2025 | |
| Aspira Women'S Health INC | $277.58 | 2022-2024 | Ova1 |
| Agile Therapeutics, INC. | $175.61 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $174.82 | 2024-2025 | Veozah |
| Organon LLC | $109.50 | 2021-2023 | Nexplanon |
| Therapeuticsmd, INC. | $69.10 | 2021-2022 | |
| Hologic Sales and Service, LLC | $59.07 | 2021-2025 | Aptima |
| Mission Pharmacal Company | $56.70 | 2021-2023 | Citranatal |
| Bayer Healthcare Pharmaceuticals INC. | $55.49 | 2021-2025 | |
| Millicent US INC | $46.28 | 2021-2024 | Intrarosa, Femring |
| Takeda Pharmaceuticals U.S.A., INC. | $41.23 | 2024-2025 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $28.80 | 2022 | |
| Daiichi Sankyo INC. | $26.22 | 2024 | Injectafer |
| Pfizer INC. | $21.33 | 2021 | |
| Sage Therapeutics, LLC | $18.29 | 2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $17.63 | 2023 | |
| Shield Therapeutics INC | $17.25 | 2024 | |
| Coopersurgical, INC. | $16.22 | 2025 | Paragard T 380a |
| Novo Nordisk INC | $14.86 | 2025 | Wegovy |
| Lilly USA, LLC | $13.91 | 2024 | Zepbound |
| Mylan Pharmaceuticals INC. | $13.41 | 2022 | |
| Myovant Sciences INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Falcone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.